Hepatic Perfusion with FUdR Utilizing an Implantable System in Patients with Liver Primary Cancer or Metastatic Cancer Confined to the Liver
作者:
SeegerJanell,
WoodcockThomas M.,
BlumenreichMartin S.,
RichardsonJ. David,
期刊:
Cancer Investigation
(Taylor Available online 1989)
卷期:
Volume 7,
issue 1
页码: 1-6
ISSN:0735-7907
年代: 1989
DOI:10.3109/07357908909038262
出版商: Taylor&Francis
数据来源: Taylor
摘要:
AbstractNineteen patients with colorectal adencarcinoma, three with cholangiocarcinoma, two with hepatocellular carcinoma, and one with carcinoid were treated with hepatic artery infusion chemotherapy. An implantable pump system was used to deliver floxuridine (FUdR), starting at 400 mg for 2 weeks with 2 weeks of rest. Eleven of 15 (73%) measurable patients with colorectal carcinoma responded. Of 6 complete responses, 4 were documented by laparotomy, including 1 with choleangiocarcinoma. Toxicity included dyspepsia and elevated liver function tests in all patients, gastric ulcer in 2, cholecystitis in 2, and sclerosing cholangitis in 3. Overall median survival for the colon cancer patients has not been reached at 16 months. Regional disease was controlled in the majority of patients treated with this regimen with acceptable toxicity and good quality of life.
点击下载:
PDF (427KB)
返 回